NECSTGEN has started a collaboration with IT-partner LINKIT. NECSTGEN is a spin out of the Leiden University Medical Center that will support clinicians, academic groups and small industrial therapy developers globally to bring cell and gene therapies to patients.

Paul Bilars, CEO of NECSTGEN: “LINKIT adds valuable knowledge and expertise the IT aspects of this field to the team. We are happy to join forces to make our shared vision possible.”

While NECSTGEN is preparing for its new development and GMP production facility to go live in 2022, it closely collaborates with LINKIT on realising a fitting IT roadmap. Sprint by sprint, and in compliance to GMP guidelines.

The project is being carried out by Jan Paul Buijs, Kees Mensch and Maaike Stoops from LINKIT.

Jan Paul Buijs adds: “Since the start of this collaboration, we feel like being part of the NECSTGEN team and its mission to bring cell and gene therapies to patients. We are happy to contribute to this exciting project!”